Saskatoon-based clinical-stage company ZYUS Life Sciences Corporation (TSXV: ZYUS) has advanced its ongoing fundraising efforts with the closing of a fourth tranche of a secured loan financing. Announced on June 24, 2026, the latest tranche added CAD$50,000 in gross proceeds and lifted the cumulative size of the Secured Loan to CAD$695,000. The financing is being provided by a lender who is an insider of the company, a structure that triggers specific disclosure and compliance requirements under Canadian securities rules.

For a clinical-stage life sciences company, access to capital is a recurring theme, and the way that capital is raised carries implications for shareholders. The ZYUS announcement is a useful example of how a smaller issuer on the TSX Venture Exchange can use a tranche-by-tranche secured loan, supported by an insider lender, to fund its operations while navigating related-party transaction regulations. This article breaks down the details of the disclosure and what they mean for those following ZYUS.

Keys Highlights

• ZYUS Life Sciences Corporation (TSXV:ZYUS) closed a fourth tranche of a secured loan financing on June 24, 2026, raising gross proceeds of CAD$50,000.

• The latest tranche brings the total Secured Loan to CAD$695,000, within an aggregate offering size of up to CAD$2,000,000.

• The lender is an insider of the company and a member of the Board, making the financing a related party transaction under Multilateral Instrument 61-101.

• The loan carries interest of 12% per annum, is pre-payable at any time without penalty, and matures six months from its effective date.

• ZYUS relied on valuation and minority approval exemptions under MI 61-101, and net proceeds will be used for general working capital.

• The company expects to close additional tranches as the financing progresses.

What the SEDAR+ Announcement Says

According to the disclosure, the company's wholly-owned subsidiary, ZYUS Life Sciences Inc. ("ZYUS Inc."), closed the fourth tranche of the secured loan financing on June 24, 2026. The tranche generated gross proceeds of CAD$50,000 and was provided by a lender who is an insider of ZYUS.

With this closing, the total raised under the Secured Loan now stands at CAD$695,000. The company indicated that it expects to close additional tranches, and noted that the aggregate offering size is up to CAD$2,000,000.

The terms of the loan are specified in the announcement. Subject to approval from the TSX Venture Exchange, the loan will be secured by a security interest granted under a general security agreement, with an exception for certain assets. The loan bears interest at a rate of 12% per annum, payable on maturity. It is pre-payable at any time without penalty or premium, and matures six months from the loan's effective date.

Because the lender is a member of the Board of Directors, the participation constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 (MI 61-101), which governs protection of minority security holders in special transactions. ZYUS stated that it relied on two exemptions under that instrument. The first is the formal valuation exemption under section 5.5(b), available because the issuer is not listed on certain specified markets. The second is the minority approval exemption under section 5.7(1)(a), available because the fair market value of the transaction is not more than 25% of the company's market capitalization.

The company also noted that it did not file a material change report more than 21 days before the issuance of the loan because the details of the transaction were settled only recently. ZYUS stated that there is no undisclosed material information, and that all independent directors approved the transaction. The net proceeds are intended for general working capital purposes. The announcement was marked NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES, a standard restriction for Canadian issuers managing cross-border securities-law considerations.

Why This Matters for Investors

For shareholders, the announcement signals two related points. First, ZYUS continues to require external capital to support its operations, which is typical of a clinical-stage life sciences company that has yet to generate significant commercial revenue. Second, that capital is being provided by an insider, which has both potential advantages and considerations that investors should understand.

On the positive side, an insider's willingness to lend capital can be interpreted as a sign of internal confidence in the company's prospects. The loan structure also avoids immediate equity dilution, since it is debt rather than a share issuance. For shareholders sensitive to dilution, a secured loan may be preferable to issuing new shares at a low price.

At the same time, related-party financings warrant attention to governance. MI 61-101 exists precisely to protect minority shareholders in transactions involving insiders, and the framework requires either formal valuations and minority approval or reliance on specific exemptions. ZYUS has relied on exemptions that are available to smaller issuers, and has stated that its independent directors approved the transaction. Investors may wish to keep these governance details in mind when assessing the financing.

Company Background

ZYUS Life Sciences Corporation is a clinical-stage life sciences company based in Saskatoon, Saskatchewan. The company is focused on developing and commercializing novel, non-opioid drug candidates for pain management. Its research centres on cannabinoid-based compounds, positioning it within the broader effort to find alternatives to opioids for managing pain.

The company conducts its activities through its wholly-owned subsidiary, ZYUS Life Sciences Inc., and trades on the TSX Venture Exchange under the symbol ZYUS. As a clinical-stage enterprise, ZYUS is engaged in the lengthy and capital-intensive process of advancing drug candidates through development, an undertaking that typically requires sustained funding ahead of any commercial revenue.

The pursuit of non-opioid pain management therapies addresses a significant area of medical need, given the well-documented risks associated with opioids. Companies operating in this space must balance scientific progress with the financial demands of research and regulatory pathways.

Potential Market Impact

The fourth tranche, at CAD$50,000, is modest in isolation, but it forms part of a larger financing programme that could reach up to CAD$2,000,000 in aggregate. The incremental nature of the tranches suggests that ZYUS is raising capital in stages as needs arise and as terms are finalized.

From a balance-sheet perspective, the secured loan adds debt at a 12% annual interest rate. While this rate reflects the risk profile typical of an early-stage issuer, it also represents a financing cost that the company will need to service. The fact that the loan is pre-payable without penalty offers flexibility, allowing ZYUS to repay early should it secure other sources of capital or improve its financial position.

The use of net proceeds for general working capital indicates that the funds are intended to support day-to-day operations rather than a specific project. For a clinical-stage company, working capital is essential to maintaining continuity while longer-term financing is explored.

Because this is a debt financing rather than an equity issuance, the immediate impact on the share count is neutral. However, investors should remain aware that ongoing capital needs are a feature of the clinical-stage business model and that future financings, whether debt or equity, may occur.

Key Risks or Things to Watch

Several factors are worth monitoring as the financing and the company's broader development efforts continue.

First, the reliance on insider funding. While insider lending can reflect confidence, continued dependence on related-party capital raises questions about access to external, arm's-length financing. Investors may watch whether ZYUS is able to attract third-party capital over time.

Second, regulatory approval. The security interest under the general security agreement is subject to TSX Venture Exchange approval. Until that approval is in place, the security arrangement remains pending.

Third, the clinical and regulatory pathway. As a clinical-stage company, ZYUS faces the inherent risks of drug development, including the possibility that candidates may not succeed in trials or obtain regulatory approval. These risks are independent of the financing but central to the investment thesis.

Fourth, the cost and maturity of the debt. The loan carries 12% annual interest and matures six months from its effective date. Short maturities mean the company will need to either repay or refinance in a relatively short window.

Finally, the broader market for cannabinoid-based therapeutics remains an evolving field, subject to scientific, regulatory and competitive developments that could affect ZYUS's commercial prospects.

Investor Takeaway

The closing of the fourth tranche of ZYUS Life Sciences' secured loan reflects the company's continued effort to fund its operations through a staged, insider-supported debt programme. With the total Secured Loan now at CAD$695,000 and an aggregate offering size of up to CAD$2,000,000, the financing provides working capital while avoiding immediate equity dilution.

Investors should weigh the potential signal of insider confidence against the governance considerations inherent in related-party transactions, as well as the financing cost and short maturity of the loan. None of this constitutes financial advice, and interested parties should review the full disclosure on SEDAR+ before drawing conclusions.

Conclusion

ZYUS Life Sciences Corporation (TSXV: ZYUS) has taken another incremental step in financing its clinical-stage operations, closing a fourth tranche of an insider-backed secured loan and bringing the total to CAD$695,000. The 12% loan, structured as a related party transaction under MI 61-101, carries a six-month maturity and is pre-payable without penalty, with proceeds directed to general working capital. As ZYUS pursues its non-opioid, cannabinoid-based pain management programme, its ability to secure ongoing funding will remain a key element of its story. Investors following ZYUS are encouraged to consult the company's official filings on SEDAR+ for the complete details of the financing.